1 thrombophilia for the clinician dr cleona duggan
TRANSCRIPT
1
ThrombophiliaFor the Clinician
Dr Cleona Duggan
2
L > R by 4 cm
L > R by 2.5 cm
24-year-old healthy woman on birth control pills
Case Study
Reprinted with permission from Moll S. Arterioscler Thromb Vasc Biol. 2008;28:373-379.
3
XIIVII
X
Clot
Va
Thrombin Antithrombin
act. protein C
Protein S
Natural Anticoagulant System
Foy P, Moll S. Curr Treat Options Cardiovasc Med. 2009;11:114-128.
506506 act. protein C
Normal Factor V
Va
Factor V Leiden
506 act. protein C
506
Va
4
DiscoveredPrevalence
Caucasians African Americans
Factor V Leiden1
1994 5% 1.2%
Prothrombin 20210 mutation2 1996 2% 0.5%
Factor V Leiden/Prothrombin 20210
1. Ridker PM, et al. JAMA. 1997;277:1305-1307.2. Varga EA, Moll S. Circulation. 2004;110:e15-e18.
5
· Prothrombin 20210 = II20210 = G20210A: mutation in promoter region, leading to increased factor II levels
Ho WK, et al. Arch Intern Med. 2006;166:729-736.
Factor V Leiden/Prothrombin 20210
· Moderate/mild risk factor for DVT/PE
· Only very mild risk factor for recurrent VTE (FVL OR, 1.41; prothrombin 20210 OR, 1.72)
· Only marginal risk factor for arterial clots
· Mild risk factor for pregnancy loss
6
Prevalence:• 1:500 (C and S) to 1:5,000 (AT)
How do you test?• Activity• >100 mutations account for each
deficiency; thus: genetic testing not done in routine practice
Acquired deficiency:• Liver disease (C, S, AT)• Warfarin therapy (C, S)• Estrogens, pregnancy (S)• Inflammatory diseases (S)• Heparin therapy (AT)• Acute thrombosis (S, AT)
Protein C, S, and Antithrombin Deficiency
Moll S. J Thromb Thrombolysis. 2006;21:7-15.
Practical point:• Always question the diagnosis!
How do you treat?• Consider AT concentrate• Severe neonatal C deficiency:
protein C concentrate
7
tPA=tissue plasminogen activator; PAI-1=plasminogen activator inhibitor 1; TAFI=thrombin activatable fibrinolysis inhibitor.
Foy P, Moll S. Curr Treat Options Cardiovasc Med. 2009;11:114-128.
Other Thrombophilias
• Elevation of factor VIII
• Elevations of fibrinogen, factors II, IX, XI
• Fibrinolysis abnormalities:– Plasminogen deficiency
– Decreased tPA levels and polymorphisms
– Elevated PAI-1 level and polymorphisms
– Elevated TAFI levels
• Myeloproliferative disorders (JAK-2 mutation)
• Paroxysmal nocturnal hemoglobinuria (PNH)
8Reprinted with permission from Pomp ER, et al. Br J Haematol. 2007;139:289-296.
Obesity and Thrombophilia
Obesity is a risk factor for VTE
Conclusion: lose weight
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Od
ds
rati
o
BMI
<20 ≥20 and <22.5
≥22.5 and <25
≥25 and <27.5
≥27.5 and <30
≥30 and <32.5
≥32.5 and <35
≥35
np 160 416 817 925 704 402 190 220nc 256 865 1236 1102 626 311 154 133
9Pomp ER, et al. Br J Haematol. 2007;139:289-296.
Obesity and Thrombophilia
BMI Risk FactorOR for Venous
Thrombosis 95% CI
OC use
< 25 No 1
≥ 30 No 3.04 1.66-5.57
≥ 30 Yes 23.78 13.35-42.34
Combined effect of BMI ≥30 kg/m2 and genetic risk factors for VTE
10Pomp ER, et al. Br J Haematol. 2007;139:289-296.
Obesity and Thrombophilia
BMI Risk FactorOR for Venous
Thrombosis 95% CI
OC use
< 25 No 1
≥ 30 No 3.04 1.66-5.57
≥ 30 Yes 23.78 13.35-42.34
Combined effect of BMI ≥30 kg/m2 and genetic risk factors for VTE
FVL
< 25 No 1
≥ 30 No 2.48 2.13-2.88
≥ 30 Yes 7.86 4.70-13.15
11Pomp ER, et al. Br J Haematol. 2007;139:289-296.
Obesity and Thrombophilia
BMI Risk FactorOR for Venous
Thrombosis 95% CI
OC use
< 25 No 1
≥ 30 No 3.04 1.66-5.57
≥ 30 Yes 23.78 13.35-42.34
Combined effect of BMI ≥30 kg/m2 and genetic risk factors for VTE
FVL
< 25 No 1
≥ 30 No 2.48 2.13-2.88
≥ 30 Yes 7.86 4.70-13.15
Prothrombin 20210
< 25 No 1
≥ 30 No 2.45 2.12-2.82
≥ 30 Yes 6.58 2.31-18.69
12Pomp ER, et al. Am J Hematol. 2008;83:97-102.
Smoking and Thrombophilia
Smoking Risk FactorOR for Venous
Thrombosis 95% CI
Factor V Leiden
No No 1
Current No 1.43 1.26-1.63
Current Yes 5.05 3.46-7.38
Combined effect of smoking and genetic risk factors for VTE
– Conclusion: stop smoking
Prothrombin 20210
No No 1
Current No 1.41 1.25-1.60
Current Yes 6.06 2.67-13.76
13
Contraceptives and Thrombosis1,2
Risk compared to women who do not
take OCP
Absolute risk/year
All women of reproductive age 1 1 : 12,500
OCP 2-6x ’d 1 : 3,000
Hetero FVL 4x ’d 1 : 3,000
Hetero FVL + OCP 20-30x ’d 1 : 500
BMI >30 + OCP 24x ’d 1 : 500
Homozygous FVL + OCP 50-100x ’d 1 : 150
BMI >30 + smoking + OCP ??? ???
Homozygous FVL + BMI >30 + smoking + OCP
??? ???
OCP=oral contraceptive; BMI=body mass index.
1. Varga E. J Genet Couns. 2007;16:261-277.2. Pomp ER, et al. Br J Haematol. 2007;139:289-296.
14
Thrombophilia Testing
15
Pros1. “Power to prevent clots”
– surgery (red flag)
– birth control pill, pregnancy
2. Explanations
3. Influence on medical treatment– choice of drug (antiplatelet vs
anticoagulation)
– length of warfarin therapy
– intensity of warfarin therapy
Pros and Cons of Thrombophilia Testing
Cons1. Cost
2. Worry
3. Bad medical advice
4. Insurance implications
Moll S. J Thromb Thrombolysis. 2006;21:7-15.
16
Any patient with
spontaneous VTE
Younger patient with VTE +
family history
Any patient
with VTE
General population
Younger patient
with VTE
Arch-conservativeUltra-liberal
Nobody
Who Should Be Tested?1-4
1. Grody WW, et al. Genet Med. 2001;3:139-148.2. Walker ID, et al. Br J Haematol. 2001;114:512-528.3. Nicolaides AN, et al. Int Angiol. 2005;24:1-26.4. Van Cott EM, et al. Arch Pathol Lab Med. 2002;126:1281-1295.5. Baglin T, et al. Br J Haematol. 2010;149:209-220.
17
Am Coll Med Geneticists, 20014 Br Committee for
Standards in Haematol, 20105
Europ Genetics Foundation, Mediterranean League on Thromboembolism, Internat. Union of Angiology, etc, 20051
Which Patient to Test for Thrombophilia?
CAP, 20022
1. Nicolaides AN, et al. Int Angiol. 2005;24:1-26.2. Van Cott EM, et al. Arch Pathol Lab Med. 2002;126:1281-1295.3. The Thrombosis Interest Group of Canada. Available at:
http://www.tigc.org/eguidelines/hypercoagstates.htm. 4. Grody WW, et al. Genet Med. 2001;3:139-148.5. Baglin T, et al. Br J Haematol. 2010;149:209-220.
Arch-conservativeUltra-liberal
Thrombosis Interest Group of Canada, 20063
18
· VTE occurring at a younger age (ie, <50 years)· Unprovoked VTE· Recurrent VTE
When to Consider Thrombophilia Testing
Foy P, Moll S. Curr Treat Options Cardiovasc Med. 2009;11:114-128.
· Thrombosis at an unusual site (splanchnic, sinus/cerebral, or renal veins)· Unusually extensive spontaneous VTE· Family history of VTE· Asymptomatic individual with family history of strong thrombophilia
– Antithrombin deficiency– Protein C deficiency– Protein S deficiency– Homozygous factor V Leiden– Homozygous prothrombin mutation– Compound thrombophilias
· Recurrent VTE while adequately anticoagulated· Unexplained arterial thromboembolism in a young person (ie, no
arteriosclerosis risk factors, no cardio-embolic source)· ≥3 unexplained pregnancy losses before week 10, or ≥1 loss after week 10
19
Family Implications of Thrombophilia
20
1. To put the person on anticoagulants
2. To manage the individual differently:· Lifestyle changes (obesity, smoking)
· Advice on oral contraceptives, hormone therapy
· Airline travel
· Pregnancy
· Surgery
Why to Test an Asymptomatic Family Member
Moll S. J Thromb Thrombolysis. 2006;21:7-15.
21
Key Points About Positive Family History
1. Noboa S, et al. Thromb Res. 2008;122:624-629.2. Bezemer ID, et al. Arch Intern Med. 2009;169:610-615.
· Positive family history (1st degree relative) is VTE risk factor (2.5-4.2 fold increased risk)2
· Risk is independent of presence of known genetic thrombophilias
· Risk is due to unknown risk factor
22
Strategy for Familial Testing
Proband’s thrombophilia
Male Family Member
Sons Brothers
Hetero FVL or hetero prothrombin 20210 no no
Homo FVL or homo prothrombin 20210 no reasonable
Double hetero reasonable reasonable
C, S, AT reasonable reasonable
“Reasonable,” because: consider LMWH with airline travel, cast, non-major surgery; prolonged after major surgeries.
“Yes,” because: advise against oral contraceptives/hormone therapy; give ante- and postpartum anticoagulation.
Slide courtesy of Moll S.
Female Family Member
Daughters Sisters
no no
no yes
yes yes
yes yes
23
Lifestyle Changes
1. Lose weight
2. Stop smoking
3. Know the symptoms of DVT and PE
4. Know the risk factors for DVT and PE
5. Know your family history